Teitur Trophics Completed Enrollment in Their Ongoing First-in-Human Phase I Trial for TT-P34 on World Parkinson’s Day

Aarhus, Denmark: 11 April 2026

Teitur Trophics, a biotechnology company developing TT-P34, a novel neuroprotective peptide for neurodegenerative diseases, today announced that enrollment of early-stage Parkinson’s patients has been completed in its ongoing Phase I clinical trial of TT-P34. The trial is being conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. This announcement coincides with World Parkinson’s Day, underscoring Teitur Trophics’ commitment to advancing disease-modifying treatments with an innovative mechanism to provide a novel treatment option for Parkinson’s disease.

‍

TT-P34 is a first-in-class cyclic peptide designed to improve lysosomal and mitochondrial functioning simultaneously. The Phase I trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of TT-P34 in healthy volunteers and Parkinson’s patients. All planned cohorts have been fully enrolled, and dosing in all trial participants has been initiated. “Completing enrollment in time and initiating dosing in the Parkinson’s cohort is a major milestone for Teitur Trophics and for the progress of our TT-P34 program,” said Simon Molgaard, CEO of Teitur Trophics. “On World Parkinson’s Day, this progress reflects our dedication to developing therapies that can meaningfully alter the course of neurodegenerative diseases”.

Teitur Addresses a Growing Need for Disease-Modifying Therapies

More than 10 million people worldwide live with Parkinson’s disease, and current treatments primarily address symptoms rather than the underlying neurodegenerative process. Teitur Trophics aims to shift this paradigm by developing disease-modifying therapies via a novel mechanism. “We are grateful to all the trial participants, and in particular to our partners at CHDR,” said Andrea Borta, CMO of Teitur Trophics. “Their contribution, and CHDR’s engagement in ensuring timely enrollment, brings Teitur one step closer to delivering an innovative therapy with the potential to slow or halt disease progression.”.

Next Steps

Topline results from the Phase I trial are expected to be presented to dedicated investors and pharmaceutical companies during the Bio International Convention in San Diego, US, in June, and at the upcoming MDS conference in Seoul, South Korea, in October. These data will inform the design of the Phase II trial in Parkinson’s patients, which is expected to begin in early 2027.

‍